Global Postoperative Pain Therapeutics Market Size By Drug Class, By Route Of Administration, By Distribution Channel, By Geographic Scope And Forecast

Postoperative Pain Therapeutics Market Size And Forecast

Postoperative Pain Therapeutics Market size was valued at USD 12.16 Billion in 2023 and is projected to reach USD 16.49 Billion by 2031 , growing at a CAGR of 3.89% from 2024 to 2031. Postoperative pain therapeutics refers to medical interventions and treatments used to manage pain experienced by patients following surgical procedures. Postoperative pain therapeutics aim to reduce suffering, increase healing, and improve overall recovery after surgery. These therapeutics include a variety of pharmacological and non-pharmacological techniques that are adapted to each patient's specific needs and the type of operation performed.

Opioids, nonsteroidal anti-inflammatory medicines (NSAIDs), and local anesthetics are popular analgesics used in pharmacological therapies. Non-pharmacological therapies include physical therapy, acupuncture, and relaxation exercises.

Furthermore, postoperative pain therapeutics are used in a wide range of medical specializations and surgical procedures, from small outpatient procedures to more invasive operations.

Postoperative Pain Therapeutics Market Dynamics

The key market dynamics that are shaping the Postoperative Pain Therapeutics Market include:

Key Market Drivers

Rising Surgical Procedures:

The global increase in surgical procedures due to aging populations, chronic diseases, and technical developments in surgery techniques is driving the need for postoperative pain therapeutics to effectively manage pain after surgery.

Awareness and Expectation for Pain Management:

Patients and healthcare providers are becoming increasingly aware of the necessity of proper pain management. As a result, advanced postoperative pain therapeutics are in high demand due to rising patient expectations for comfortable recovery times.

Pharmaceutical Innovations and Approvals:

The development and approval of new and effective pain treatment medications, including non-opioid alternatives, are important drivers. Drug delivery system innovations that provide longer pain relief while minimizing negative effects also helping drive market.

Government and Healthcare Policies:

Government rules and guidelines encouraging effective pain management standards in healthcare facilities stimulate the use of sophisticated therapeutics. Reimbursement rules that favor pain management medications and therapies are propelling the Postoperative Pain Therapeutics Market.

Key Challenges:

Opioid Crisis and Regulation:

The opioid crisis has resulted in stringent opioid prescription laws, which pose hurdles for players in the market. The demand for non-opioid pain treatment solutions is growing, but creating alternatives that are as effective as opioids is complicated.

Side Effects of Pain Management Drugs:

Many postoperative pain management medicines have side effects, such as nausea, vomiting, constipation, and the potential for addiction is discouraging their usage. Developing medications with minimal side effects is also an important challenge in the market.

Clinical and Regulatory Hurdles:

Bringing innovative pain management products to market needs extensive clinical testing and regulatory authorization. These processes are time-consuming and costly, creating significant barriers to the entry of novel medications and technologies into the Postoperative Pain Therapeutics Market.

Key Trends:

Increasing Demand for Non-Opioid Medications:

Concerns about opioid addiction are driving a huge shift towards non-opioid therapies. Thus, pharmaceuticals are developing non-addictive pain management treatments that effectively cure postoperative pain without the hazards of opioids.

Rise of Multimodal Pain Management:

Multimodal pain management, which combines several approaches and drugs to treat pain, is becoming increasingly popular in the market. This method attempts to improve pain relief and minimize adverse effects, resulting in faster patient recovery and shorter hospital stays.

Growth in Ambulatory Surgical Centers:

Effective postoperative pain therapeutics are in high demand due to the growth of ambulatory surgical centers (ASCs). ASCs provide a cost-effective alternative to hospital-based surgeries, focusing on reducing patient recovery time and enhancing pain management protocols.

Advancements in Drug Delivery Systems:

There is a rising emphasis on creating novel medication delivery systems, such as transdermal patches and implanted devices, to improve the efficacy and convenience of post-operative pain management. These technologies provide regulated medication release, resulting in constant pain relief without frequent dosage.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Postoperative Pain Therapeutics Market Regional Analysis

Here is a more detailed regional analysis of the Postoperative Pain Therapeutics Market:

North America:

According to Verified Market Research, North America is estimated to dominate the Postoperative Pain Therapeutics Market during the forecast period. North America has an important number of surgical procedures due to sophisticated healthcare infrastructure and patient access to medical care, driving the demand for postoperative pain therapeutics to successfully manage recovery.

With the present opioid crisis in this region, there is a tremendous push for non-opioid pain management alternatives. Regulatory agencies and healthcare practitioners are concentrating on safer, more effective ways to manage postoperative pain without contributing to addiction.

The presence of major pharmaceutical companies and research institutions in North America promotes the development of innovative pain management medicines, such as non-opioid medications and novel drug delivery methods is propelling the growth of the market.

Furthermore, the expansion of ambulatory surgical centers (ASCs) in North America, which provide cost-effective and efficient surgical treatment is demanding enhanced postoperative pain management options to ensure timely recovery and patient satisfaction.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR within the market during the forecast period. Asia Pacific is experiencing tremendous growth in healthcare infrastructure, including hospitals and surgical centers, to accommodate an increasing number of surgical procedures that necessitate adequate postoperative pain treatment.

The growing older population in countries such as Japan, China, and India, which are more prone to chronic illnesses necessitate surgical procedures, thereby boosting demand for postoperative pain therapeutics.

Healthcare professionals and patients are becoming more conscious of the necessity of appropriate pain management, driving up demand for sophisticated treatments in the Postoperative Pain Therapeutics Market in this region.

Furthermore, economic development in the Asia-Pacific region has resulted in increasing healthcare spending and medical research investments, facilitating access to the development of advanced postoperative pain management options.

Europe:

Europe's stringent regulatory framework for pain management medications, particularly opioid use, fuels demand for innovative and safer postoperative pain therapies.

With a significant number of elective and non-elective surgeries conducted each year, Europe has a high demand for efficient postoperative pain management solutions to improve patient recovery and shorten hospital stays.

To provide comprehensive pain relief following surgery, European healthcare systems are increasingly implementing multimodal pain treatment strategies that combine pharmaceutical and nonpharmacological approaches.

Furthermore, Europe's dedication to healthcare innovation, which includes the development of innovative drug delivery methods and non-opioid drugs, helps to drive market growth for postoperative pain treatments by providing effective and patient-friendly alternatives.

Postoperative Pain Therapeutics Market: Segmentation Analysis

The Global Postoperative Pain Therapeutics Market is segmented based on Drug Class, Route Of Administration, Distribution Channel, And Geography.

Postoperative Pain Therapeutics Market, By Drug Class

• Opioids
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Local Anesthetics
• Tricyclic Antidepressants
• Antiepileptic Drugs
• Others

Based on Drug Class, the market is segmented into Opioids, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, and Others. The opioids segment is estimated to dominate the Postoperative Pain Therapeutics Market due to their effectiveness in managing moderate to severe pain. Despite increasing concerns about addiction and the search for non-opioid alternatives, opioids remain popular in the postoperative setting due to their superior efficacy in treating acute pain. Opioids are used by healthcare practitioners for acute pain treatment after surgery, especially when the intensity of the pain exceeds the analgesic capacity of NSAIDs or local anesthetics.

Postoperative Pain Therapeutics Market, By Route Of Administration

• Oral
• Intramuscular
• Intravenous
• Others

Based on the Route Of Administration, the market is segmented into Oral, Intramuscular, Intravenous, and Others. The intravenous segment is estimated to dominate the Postoperative Pain Therapeutics Market during the forecast period. The intravenous route is preferable in hospitals due to its rapid start of action, accurate dosage control, and capacity to offer continuous pain relief, all of which are critical for managing acute postoperative pain. Furthermore, intravenous delivery is extremely beneficial for individuals who are unable to take oral drugs due to postoperative restrictions or nausea. The efficiency, control, and quick comfort given by the intravenous injection make it an essential component of postoperative therapy, assuring its market domination.

Postoperative Pain Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The hospital pharmacies segment is estimated to dominate the market over the forecast period. This dominance is due to hospital pharmacies' direct involvement in the patient care process, particularly during the early postoperative period. Hospital pharmacies play an important role in the healthcare delivery system, ensuring that critical pain management drugs are available quickly after surgical procedures. This segment's popularity is bolstered by the high volume of surgeries conducted in hospitals, where thorough pain management protocols are vital to patient care, making hospital pharmacies an important component of the Postoperative Pain Therapeutics Market.

Key Players

• The " Global Postoperative Pain Therapeutics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• AbbVie, Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Baxter International Inc., Zimmer Biomet Holdings Inc., Boston Scientific Corporation, Medtronic plc, Stryker Corporation, Becton, Dickinson and Company, Smith & Nephew plc, and Altaris Therapeutics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In February 2024, Pacira BioSciences announced positive findings from a Phase 3 trial of its long-acting local anaesthetic EXPAREL(R) in patients having bunionectomy surgery. The trial attained its primary goal of showing a statistically significant reduction in pain levels when compared to placebo.
• In January 2024, Collegium Pharmaceutical introduced its new Xtampza ER(R) (oxycodone hydrochloride) extended-release tablets in a new 20mg dosing strength. This broadens the product portfolio for treating moderate-to-severe chronic pain.
• In January 2024, Grunenthal demonstrated positive results from a Phase 2 research of its new nerve growth factor (NGF) inhibitor, Qsymia(R) (resiniferatoxin), for the treatment of post-surgical neuropathic pain. The findings revealed significant increases in pain levels and quality of life when compared to placebo.
• In January 2024, Aprecia Pharmaceuticals expanded its Sprintec(R) (Aprecia Melt) line of fast-dissolving sublingual films with the introduction of Aprecia Melt Zuplenz(R) (ondansetron) for the prevention and management of nausea and vomiting associated with surgery.
• In January 2024, Xeris Pharmaceuticals published findings from a Phase 2 study of GLYENA(R), a novel sustained-release local anaesthetic, for the treatment of postherpetic neuralgia. The findings revealed significant increases in pain levels and quality of life when compared to placebo.